CCDC6 and neoplasm: As expected, USP7 inhibitors (like P5091) can downregulate CCDC6 protein levels and favor tumor cells sensitivity to PARP inhibitors in non-small cell lung cancer (Morra et al., 2015), lung neuroendocrine cancer (Malapelle et al., 2017) and hormone-sensitive and castration-resistant prostate cancer (Morra et al., 2017).